Laparoscopic ileocolic resection versus infliximab treatment of recurrent distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).

Gepubliceerd: 03-12-2007 Laatst bijgewerkt: 13-12-2022

Laparoscopic ileocolic resection may be more effective than infliximab treatment in recurrent Crohn´s disease located in the terminal ileum improving quality of life and reducing costs.

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON21700

Bron
NTR

Verkorte titel
LIR!C-trial (LIRIC-trial)

Aandoening

Engels: recurrent Crohn´s disease located in the terminal ileum, infliximab, ileocolic resection, QALY, Laparoscopy.
(NLD: recidiverende ziekte van Crohn in het terminale ileum, infliximab, ileocecaal resectie, QALY, laparoscopie).

Ondersteuning

Primaire sponsor: Academic Medical Center (AMC)
Overige ondersteuning: ZON-MW, The Netherlands Organization for Health Research and Development

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

1. Disease-specific quality of life, as measured with the IBDQ;
2. Costs per QALY.

Toelichting onderzoek

Achtergrond van het onderzoek

Recurrent Crohn’s disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Once started infliximab should be given at regular 6 to 12 weeks intervals and is combined with other immunosuppressive drugs. Infliximab is an expensive treatment and it is currently unknown how long the treatment should be continued. Patients that need this type of treatment have a reduced quality of life. Surgical resection is an accepted alternative treatment. Laparoscopic ileocolic resection is as safe as open surgical resection, yielding shorter hospitalization and better cosmesis. Therefore, when disease activity is limited to the ileum this intervention maybe cheaper, more effective and resulting in a better quality of life.
The objective of this project is a comparison of the effectiveness and costs of infliximab treatment with laparoscopic ileo-colic resection in patients with recurrent Crohn’s disease of the distal ileum.
The study is designed as a multicenter randomized clinical trial including patients with Crohn’s disease located in the terminal ileum that require infliximab treatment following recent consensus statements on IBD treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are defined as costs and treatment efficacy defined by hospital stay, early and late morbidity, sick leave, quality of life and surgical recurrence.. In order to detect an effect size of 0.5 on the IBDQ at a 5% two sided significance level with a power of 80% a sample size of 65 patients per treatment is estimated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs will be compared and the costs per QALY calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from November 2007 until November 2009.

Doel van het onderzoek

Laparoscopic ileocolic resection may be more effective than infliximab treatment in recurrent Crohn´s disease located in the terminal ileum improving quality of life and reducing costs.

Onderzoeksopzet

N/A

Onderzoeksproduct en/of interventie

1. Infliximab: remission induction - three subsequent infusions at week 0, 2 and 6 in a dose of 5 mg/kg; maintenance therapy - infusions of 5 mg/kg at 8 to 12 weeks intervals in case of active disease after infliximab remission induction treatment. In case of disease recurrence during infliximab treatment intervals will be shortened to 6 weeks and/or the dose level increased to 10 mg/kg;

2. Laparoscopic ileocolic resection: prior to surgery remission induction consisting of prednisolone 40 mg OD for two weeks, 30 mg OD during two weeks and 25 mg OD for 1 week, followed by a dose 20 mg OD Once steroid therapy has been tapered to a dose of 20 mg/day ileocolic resection can be performed.

Contactpersonen

Publiek

Dept. of Surgery and dept. of Gastroenterology & Hepatology Academic Medical Center

E.J. Groof, de
Amsterdam
The Netherlands
+31 (0)20 566 2670

Wetenschappelijk

Dept. of Surgery and dept. of Gastroenterology & Hepatology Academic Medical Center

E.J. Groof, de
Amsterdam
The Netherlands
+31 (0)20 566 2670

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Age in between 18 and 80 years;

2. recurrent Crohn's disease of the distal ileum;

3. a stable dose of immunomodulatory therapy for at least 8 weeks;

4. a completed IBDQ and EQ-5D before randomization;

5. informed consent.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Prior ileocolic resection for Crohn's disease;

2. Obstructive Crohn's disease of the distal ileum requiring surgery;

3. diseased small bowel segment longer than 40 cm;

4. abdominal abscesses, fistula's and abdominal fluid collections;

5. ASA III en iV;

6. Co-morbidity requiring infliximab treatment.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blindering:	Open / niet geblindeerd
Controle:	Geneesmiddel

Deelname

Nederland

Status:	Werving gestart
(Verwachte) startdatum:	01-12-2007
Aantal proefpersonen:	142
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	03-12-2007
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1115
NTR-old	NTR1150
Ander register	subsidie : 80-82310-98-08105
ISRCTN	ISRCTN wordt niet meer aangevraagd

Resultaten

Samenvatting resultaten

N/A